Cosmos Health stock trades at USD 0.34, 72.6 percent below its high

Published on 10/15/2026 at 20:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 19.32 million in the second quarter. Cosmos Health stock costs EUR 0.30 on October 15, 2026 at 8:38 p.m. CEST.

Revenue and valuation details

Revenue reached USD 19.32 million in the second quarter of 2026.
Cosmos Health had a USD 33.9 million market capitalization on October 15, 2026.
Cosmos Health stock costs EUR 0.30 at Lang & Schwarz on October 15, 2026 at 8:38 p.m. CEST.

COSM, US2214133058, Illustration mit AI erstellt.

Cosmos Health stock traded at USD 0.34 on Nasdaq on October 15, 2026 at 2:38 p.m. ET, while the euro quote stood at EUR 0.30 at Lang & Schwarz at 8:38 p.m. CEST. The Nasdaq price was 72.6 percent below the stock's USD 1.24 52-week high.

Second-quarter revenue sets the base

In the second quarter of 2026, Cosmos Health reported revenue of USD 19.32 million and earnings per share of minus USD 0.10, according to Investing.com. The latest reported quarter therefore combined a sizeable sales base with a loss, a contrast that keeps operating performance central to the valuation discussion.

For comparison, the finance figures place Cosmos Health at a market capitalization of USD 33.9 million and a negative price-to-earnings ratio of 0.51 as of October 15, 2026. The stock's 52-week range runs from USD 0.16 to USD 1.24, leaving the current Nasdaq quote much closer to the low than the high.

Price position and liquidity

The Nasdaq quote was last at USD 0.34 on October 15, 2026 at 2:38 p.m. ET. Trading volume reached 2,335,969 shares against an average volume of 3,559,029 shares, while the session range was USD 0.33 to USD 0.38. The euro indication was EUR 0.30 at Lang & Schwarz at 8:38 p.m. CEST.

Cosmos Health's market value is small relative to the two larger pharmaceutical companies in the comparison below. That gap matters because a low share price does not by itself indicate a low or high valuation.

Comparison with peers

Cosmos Health (Nasdaq, USD): minus 12.01 percent, P/E minus 0.51, market capitalization USD 33.9 million.

Pfizer (NYSE, USD): plus 1.39 percent, P/E 39.15, market capitalization USD 168.8 billion.

Teva Pharmaceutical Industries (NYSE, USD): plus 1.31 percent, P/E 69.51, market capitalization USD 48.1 billion.

Recent operating signals

Cosmos Health had reaffirmed its full-year 2026 revenue outlook above USD 90 million in an October 7, 2026 filing, while preliminary nine-month revenue reached USD 54.3 million, up 19 percent year over year, according to StockTitan. Those figures are preliminary and unaudited, so the next complete quarterly filing will be important for testing the outlook against reported results.

Euro quote after the Xetra close

The euro quote stood at EUR 0.30 at Lang & Schwarz on October 15, 2026 at 8:38 p.m. CEST. The Nasdaq price was USD 0.34 at 2:38 p.m. ET on the same date, and the 52-week Nasdaq range was USD 0.16 to USD 1.24. The further course of trading is shown by the continuously updated real-time quote of Cosmos Health stock.